| Stereochemistry | ACHIRAL |
| Molecular Formula | C10H11Cl2N3 |
| Molecular Weight | 244.12 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=C(Cl)C=C(CC2=NCCN2)C=C1Cl
InChI
InChIKey=FXNNRWAIGIEAST-UHFFFAOYSA-N
InChI=1S/C10H11Cl2N3/c11-7-3-6(4-8(12)10(7)13)5-9-14-1-2-15-9/h3-4H,1-2,5,13H2,(H,14,15)
Nemazoline (A-57219) is a nasal decongestant. It has alpha 1-agonist/alpha 2-antagonist activity and was more effective and long-acting than oxymetazoline on canine nasal mucosa, in-vitro and in-vivo. Upon intranasal administration to dogs, the compound was devoid of systemic effects up to a concentration 1000 times that needed for local decongestant effect (1.65 micrograms, atomized from a 1 microgram mL-1 solution) suggesting limited mucosal absorption. After nasal administration to rats for 15 days at a concentration 1000 times greater than that required for nasal decongestion, no mucosal tissue toxicity or systemic effects were seen.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 576.0 nM [Ki] | |||
| 29.0 null [Ki] |
PubMed
Patents
Sample Use Guides
Upon intranasal administration to dogs, the compound was devoid of systemic effects up to a concentration 1000 times that needed for local decongestant effect (1.65 ugrams, atomized from a 1 ugram mL-1 solution) suggesting limited mucosal absorption.
Route of Administration:
Nasal
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
